Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TITLY

Financiado

Cerrado

Inhibition of the T cell receptor signalling pathway for treatment of T cell lym...

Inhibition of the T cell receptor signalling pathway for treatment of T cell lymphoma Non-Hodgkin lymphoma (NHL) is a form of cancer emerging from the transformation of a mature B- or T-cell lymphocyte. NHL is the 11th most common cancer in Europe, and the 10th most common cancer worldwide. Functional evidence of t... ver más

31/10/2017

CNRS

179K€

Presupuesto del proyecto: 179K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-10-31

MSCA-IF-2014-GF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

CNRS

178.60K€ | Lider

United States Department of...

HHS

86.07K€ | Participante

Proyectos interesantes

BCRES-CLL

Medical Technol...

Data Science

183K€ Cerrado

IGpath

Medical Technol...

Data Science

153K€ Cerrado

Autonomous CLL-BCRs

Medical Technol...

Data Science

2M€ Cerrado

LeukemiaEnviron

Medical Technol...

Data Science

1M€ Cerrado

RTI2018-101345-B-I00

Medical Technol...

Immunology

121K€ Cerrado

LYMPHOSIGN

Medical Technol...

Data Science

200K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 30 meses Fecha Inicio: 2015-04-14
Fecha Fin: 2017-10-31

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 179K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Non-Hodgkin lymphoma (NHL) is a form of cancer emerging from the transformation of a mature B- or T-cell lymphocyte. NHL is the 11th most common cancer in Europe, and the 10th most common cancer worldwide. Functional evidence of the key role of B-cell receptor (BCR) signalling in B-cell malignancies came mainly from works conducted in Dr Louis Staudt’s lab (National Cancer Institute, Lymphoid Malignancies Branch, Bethesda, USA) where the outgoing phase of the global fellowship would take place. Rapid translation of basic science discovery on the BCR signalling led to the development of a specific inhibitor of a key BCR pathway adaptor named Bruton’s tyrosine kinase (BTK), which was granted for accelerated approval both in United States and Europe by regulatory medical agencies. While the potency of BCR pathway inhibitors is currently revolutionizing the management of B-cell malignancies, peripheral (ie mature) T-cell lymphomas (PTCL) still share a dismal prognosis with a 10-year overall survival barely exceeding 15%. Previous work of the experienced researcher provides strong evidence that PTCL similarly rely on T-cell receptor (TCR) signalling pathway for survival. Targeting this pathway could then lead to discovery of potent therapeutic compounds for PTCL treatment. During the 2 years of the global fellowship, the researcher would first perform a TCR pathway small hairpin RNAs (shRNAs) loss-of-function screen in PTCL cell lines in the group of Dr Louis Staudt where the technic is already available and has been fruitfully applied to B-cell malignancies. Second, the researcher would identify potential pharmacological inhibitors of the previously identified targets both in vitro and in vivo in PTCL cell lines xenograft models. This second phase of the project would take place both among the outgoing team and the return group of Pr Gilles Salles (Centre National de la Recherche Scientifique, Indolent-B-cell Proliferation Branch, Lyon, France).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores